Realizing the promise.
We are at the cusp of a revolution in medicine. Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs.
Aoife Brennan, MB, BCh, BAO, MRCPI
Aoife Brennan, MB, BCh, BAO, MRCPI
Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic’s president and chief executive officer since May 2018. She joined Synlogic in September 2016 as chief medical officer. Prior to Synlogic, Aoife spent six years at Biogen, most recently as vice president and head of the Rare Disease Innovation Unit, developing programs from pre-clinical to commercial. She has led programs across multiple therapeutic areas including the successful late phase development & registration of SPINRAZA® (nusinersen) for spinal muscular atrophy and ALPROLIX® and ELOCTATE® for Hemophilia B and Hemophilia A, respectively.
Aoife serves as a member of the Board of Directors of Cerevance and Fibrogen, Inc, and previously served on the Board of Directors of Ra Pharmaceuticals until it’s acquisition by UCB. Earlier in her career, Aoife led clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes.
Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Antoine Awad
Antoine Awad
Molly Harper
Molly Harper
Ms. Harper is an experienced biotech leader with a demonstrated track record of translating development assets into commercialized products. Ms. Harper joins Synlogic from Relmada Therapeutics, Inc. where she served as Executive Vice President of Operations. Prior to Relmada she served in positions of increasing responsibility with Akcea Therapeutics, including most recently as Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the commercialization of two rare disease drugs. Ms. Harper was also Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme, having previously served at various positions in sales and marketing with Merck & Co, and equity research at UBS Warburg. She is also a member of the Board of Directors for Catalyst Pharmaceuticals and PreciseDx.
DAVID HAVA, PHD
David Hava, PhD
Michael Jensen
Michael Jensen
Prior to joining Synlogic, Michael was the CFO at Intrinsic Therapeutics, a commercial-stage medical device company focused on delivering treatments to improve surgical efficacy. Prior to Intrinsic, Michael held financial leadership roles at several biotech and healthcare companies including Taconic Biosciences, Straumann North America, Siemens Healthcare Diagnostics, Novartis, and Novo Nordisk Inc. He holds a Master of Economics and Business Administration degree from Copenhagen Business School in Copenhagen, Denmark, and a Bachelor of Business Administration degree from Towson University in Baltimore, MD. He also served as an Officer in the Royal Danish Army.
Caroline B. Kurtz, PhD
Caroline B. Kurtz, PhD
Brendan St. Amant
Brendan St. Amant
